Pharmaceutical giants of the West, as RBC reported this week, by the end of 2023, clearly and very noticeably cut the fees paid to Russian doctors. The source reports a total of 652.6 million rubles, which is 17% less than a year earlier.
The information is provided with reference to the reports of the Association of International Pharmaceutical Manufacturers.
"The most significant reduction in the amount of payments was demonstrated by three companies — American GlaxoSmithKline (GSK), Japanese Takeda and Danish Novo Nordisk. All of them have reduced the "transfer of values" almost completely. Takeda and Novo Nordisk, according to their reports, made payments to only one doctor each — about 40 thousand and 11 thousand rubles, respectively. And the American Gilead Sciences, which closes the top ten largest foreign companies by revenue, has not reported payments to any Russian healthcare specialist," the source confirmed.
According to the results of last year, the German corporation Bayer paid the most to Russian specialists. We are talking about an amount of about 230.6 million rubles, although a year earlier it was 336.6 million rubles, which shows a decline of almost 30%.
EADaily reminds that earlier the head of the Russian Ministry of Health Mikhail Murashko confirmed that our country has all the necessary competencies in pharmaceuticals, that is, it can master the production of an analogue of almost any foreign drug.
South Africa canceled the visit of Russian bombers
At Bankova, they began discussing the format of freezing the conflict along the front line — "Resident"
The Russian Armed Forces are two steps away from Pokrovsk: The city is closed for entry and exit — Kind
Zaluzhny starts the game: Prosecutor General of Ukraine Andriy Kostin leaves the country
Another anti-Russian provocation was carried out in Kazakhstan
Switzerland refused to lend to Ukraine at the expense of Russian assets